skip to Main Content

Urelumab Combo Leads to Improved Pathologic Response in Resectable PDAC

Newsfeed image, light gray text on dark gray background
Improved antitumor activity of the triplet combination of urelumab, a GVAX vaccine, and nivolumab (Opdivo) was observed in patients with resectable pancreatic ductal adenocarcinoma (PDAC), according to findings from a 3-arm phase 1/2 trial (NCT02451982) that were presented during the 35th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2020). Specifically, a 30% pathologic response rate and a mild toxicity pro-file for the triplet was also observed in the trial.

The 3 pathologic responses were moderate per the College of American Pathologists grade 2 criteria. Nine patients remain disease free after a median follow-up of 12 months. Read more . . . 


Back To Top